Compare Rambus Inc. Common Stock (RMBS) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rambus Inc. Common Stock vs Smith & Nephew plc — how do they compare? Rambus Inc. Common Stock trades at $89.17 (market cap $10.66B), while Smith & Nephew plc trades at $28.24 (market cap $11.60B). The key difference: Rambus Inc. Common Stock and Smith & Nephew plc are close in size by market cap, and Smith & Nephew plc pays a 2.85% dividend while Rambus Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Rambus Inc. Common Stock for 0 Days and Smith & Nephew plc for 121 Days on average.
| RMBS | SNN | |
|---|---|---|
Market Cap | $10.66B | $11.60B |
Volume | 2,136,075 | 971,836 |
Sector | Technology | Health |
52-Week High | $170.66 | $37.17 |
52-Week Low | $79.73 | $26.42 |
Typical Hold Time | 0 Days | 121 Days |
Enterprise Value | $9.85B | $14.63B |
Dividend Yield | — | 2.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Rambus (RMBS) trades at $98.17, down 2.84% over 24 hours, with a neutral technical signal and key support at $96. The company reported strong profitability with a 31.69% net income margin and beat EPS estimates in two of the last three quarters. Recent news highlights its focus on AI infrastructure with new product launches, positioning it to benefit from growing demand for high-speed memory solutions.
The outlook is positive given analyst consensus of a $161.75 price target and 78.57% buy ratings, but risks include high valuation multiples and competitive pressures. Execution on AI-driven growth and maintaining earnings momentum are critical for stock appreciation, while any miss in upcoming results could pressure the premium valuation.
SNN trades at $27.88, near its 52-week low, with a mixed technical signal but improving fundamentals. Revenue grew to $6.16B in 2025, with net income margin expanding to 10.08%. Recent product launches like the EVOS PELVIC System and FLOW FLEXTEND COBLATION Wand highlight innovation, though the stock faces bearish moving averages and neutral oscillators.
Outlook is cautious; strong profitability and cash flow support value, but analyst consensus is predominantly Hold amid competitive pressures and recent CFO departure. Risks include execution challenges and debt levels, yet institutional interest from BlackRock's $505M investment signals confidence. The stock offers potential for recovery if operational targets are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Rambus Inc. Common Stock
Rambus Inc. is a semiconductor and silicon IP company that licenses chip interface and security technologies, including memory interface chipsets for DDR5 and DDR4 server and client DIMMs, interface IP for PCIe, CXL, and HBM, and security IP such as Root of Trust and memory encryption. It serves data center, AI, automotive, and IoT markets.
Read more on RMBS →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
